New York, New York--(Newsfile Corp. - February 24, 2023) - Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics ("Nektar" or "Nektar Therapeutics") (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.
The investigation concerns whether members of Nektar's board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.
INVESTORS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR NKTR STOCK SINCE AT LEAST JUNE 2022ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR NKTR SECURITIES.
SHAREHOLDERS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR STOCK SINCE AT LEAST JUNE 2022 ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, JKEHOE@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff-side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.
This press release may constitute attorney advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156182
